## **Activation of** *6-end0* **over** *5-ex0* **Epoxide Openings. Ring-selective Formation of Tetrahydropyran Systems and Stereocontrolled Synthesis of the ABC Ring Framework of Brevetoxin B**

## **K. C. Nicolaou,\* M. E. Duggan, C-K. Hwang, and P. K. Somers**

*Department of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania 19104, U.S.A.* 

**A** new synthetic strategy for the regio- and stereo-specific synthesis of tetrahydropyran systems involving *6-end0*  epoxide openings and its application to the construction of the **ABC** ring system of brevetoxin **B** are described.

In a programme directed towards the total synthesis of the complex marine toxin brevetoxin **B** (1),<sup>1</sup> currently under way in these laboratories, we needed stereospecific methods for the construction of tetrahydropyran systems. Our present strategy reduces this problem to (a) allylic alcohol formation; (b) epoxidation; and (c) epoxide openings. While for solutions to operations (a) and (b) we could turn to existing methods, a well defined strategy for the regioselective *6-endo* openings of epoxides by internal nucleophilic oxygen was absent.2 In this communication we report a stereospecific route to tetrahydropyrans from epoxy-alcohols *via* activation of the *6-endo* over the usually favoured *5-exo3* modes of epoxide opening and the application of this new technology to the stereocontrolled synthesis of the **ABC** ring system of brevetoxin B **(1)** in enantiomerically pure form.

Scheme 1 focuses on the present problem and its solution.



**Brevet ox** in ( **1** 1

Theoretically, the epoxy-alcohol (I) could suffer ring closure (under acidic or basic conditions) *via* a *5-exo* mode (path **b)** or a 6-endo (path **a)** mode of cyclization leading to a tetrahydrofuran or a tetrahydropyran system respectively. When both carbon atoms bonded to oxygen are secondary and the adjacent centres are sp3 as in case **(2)** conventional considerations suggest the *5-exo* mode (path **b)** of cyclization as the preferred pathway based mainly on geometric and kinetic constraints. Indeed, experiment confirms this hypothesis, the tetrahydrofuran system **(2b)** being the exclusively observed product (CSA cat., CH<sub>2</sub>Cl<sub>2</sub>, -20 to 25 °C). The placement of a suitable substituent in group R with the ability to weaken the adjacent C-0 bond and/or stabilize an adjacent positive charge was expected to reverse this ring selectivity, favouring the 6-endo ring closure and the formation of the tetrahydropyran system. A carbon-carbon  $\pi$  bond, being simple to introduce and useful for further elaboration, was chosen as a 'director functionality,' as seen in Scheme 1. Substrates **(3), (4),** and **(5)** were expected to show increasing ability to favour the *6-* over the 5-membered ring on electronic grounds. Indeed, **(3)** exhibited partially the expected effect **[CSA** cat., CH<sub>2</sub>Cl<sub>2</sub>,  $-40$  to 25 °C, *ca.* 60 : 40 mixture of **(3a)** and **(3b)** and **(4)** and **(5)** produced, exclusively and in high yield, the corresponding tetrahydropyran systems **(4a)** and **(5a).** The starting substrates (I) can be prepared by a general, highly efficient strategy and in high enantiomeric purity# and the described cyclizations proceed in excellent yields with complete regio- and stereo-control (inversion). **0** 

The potential of this technology for the construction of several of the 6-membered rings of brevetoxin B **(1)** is obvious. Below we demonstrate its applicability in the brevetoxin **B** project and in complex situations with the synthesis of the key intermediates **(25)** and **(26)** (Scheme 2), containing the **ABC** ring framework of this target molecule.fl Reaction of the commercially available tri-0-acetyl-D-glucal

t Under basic conditions (KOBut-Bu<sup>t</sup>OH; 25 °C) substrate (4) afforded a mixture of 6-end0 and 5-exo products [(4a): **(4b),** *ca.*  50 : 50, *85%* yield] whereas the dibromovinyl epoxide *(5)* suffered mainly 5-exo ring closure with concomitant dehydrobromination leading to the acetylenic bromide (i) accompanied by small amounts of the 6-end0 product (5a) [(i) : (5a), *ca.* <sup>95</sup>: 5; 90% yield]. Cyclizations of substrates (2) and (3) under these conditions were complicated by ester hydrolysis and were not fully explored.



 $\ddagger$  Substrates (I)  $[(3)$ —(5)] were obtained from pent-4-yn-1-ol in a straightforward manner by (i) silylation (Bu'Me<sub>2</sub>Si); (ii) hydroxymethylation (BunLi- $[CH_2]_nO$ ); (iii) RedAl reduction; (iv) Sharpless asymmetric epoxidation;<sup>7</sup> (v)  $SO_3$  pyridine [O]; (vi) Wittig reaction; (vii) desilylation. Compound (2) was obtained by diimide reduction of silylated **(3)** followed by step (vii).

**fj** The structures of the cyclized products were established as follows. (2b): y-lactone formation  $[p\text{-MeC}_6H_4SO_3H, C_6H_6; i.r.$  (CHCl<sub>3</sub>)  $v_{\text{max}}$ . 1775 cm-1; 1H n.m.r. analysis]; (3a), **(3b):** MnO, oxidation converted **(3b)** into an enone leaving unchanged (3a), 1H n.m.r. analysis; (4a) and (5a) : 1H n.m.r. spectra of the corresponding acetates exhibited a double triplet *(J* 10.0 and 5.0 Hz) for CHOAc **[6** 4.63 for **(4a)** and 4.68 for (5a)l as expected for the tetrahydropyran system.

**7** All new compounds exhibited satisfactory spectroscopic and analytical and/or exact mass data. Yields refer to spectroscopically and chromatographically homogeneous materials. Product ratios were determined by n.m.r. spectroscopy and/or isolation and are within  $\pm$ 1% accuracy.



**Scheme 1.** Ring selectivity in epoxide openings. Conditions: camphorsulphonic acid (CSA) (0.1 equiv.),  $CH_2Cl_2$ , -40 to 25 °C. <sup>a</sup> Determined by  ${}^{1}$ H n.m.r. spectroscopy. b Isolated yield.

**(6)** and allyltrimethylsilane in  $CH_2Cl_2$  in the presence of  $TiCl<sub>4</sub><sup>4</sup>$ at **-78 "C** yielded, after treatment with potassium carbonate in methanol, the C-glycoside diol(7) in 95% overall yield and *ca.*  $10:1 \alpha:\beta$  anomeric ratio. Compound (7) was then transformed by standard methods to the aldehyde **(10)** *via* the tosylate *(8)* and the nitrile **(9)** in 80% overall yield. Condensation of  $(10)$  with excess of  $Ph_3P=CHCO_2Me$  led to the hydroxy-ester **(11)** (86%) which was then smoothly converted into the ketone **(12)** by Swern oxidation.5 While a number of organometallic reagents (e.g. Li, Mg, and Ti) failed to give the desired selectivity, the use of  $\text{AlMe}_3$  led to remarkable results. Reaction of AlMe<sub>3</sub> with (12) in 1:1 stoicheiometry  $\left( \text{CH}_2 \text{Cl}_2 \right)$ , PhMe,  $-15 \text{ }^{\circ}\text{C}$ ) proceeded in excellent yield but with a 20:1 preference for  $(13)$  by  $\beta$ -attack, whereas slow addition of  $(12)$ to excess of  $\text{AlMe}_3$  (4 equiv.) reversed the preference of attack resulting in a *ca.* 3 : 1 ratio of **(14)** to its epimer **[94%** total yield from (11)] as expected from the elegant studies of Ashby *et al.*<sup>6</sup> Silylation of pure **(14)** followed by reduction (Bu<sup>1</sup><sub>2</sub>AlH) of the ester group and Sharpless asymmetric epoxidation<sup>7</sup> led to the epoxide **(15)** (64% overall) which was then oxidized under Swern conditions and treated with  $Ph_3P-CBr_4^8$  to give, after desilylation, the hydroxy-epoxide **(16)** (63% overall yield).

6-endo-Cyclization of **(16)** was then smoothly effected by catalytic amounts of CSA  $(CH_2Cl_2, 25 °C)$  furnishing the bicyclic system  $(17)$ <sup>\*\*</sup> with complete regio- and stereoselectivity as suggested by n.m.r. spectroscopy and subsequently proved by  $X$ -ray analysis on a more advanced intermediate *(vide infra).* Silylation of **(17)** gave **(18)** (100%) which on treatment with excess of Bu<sup>n</sup>Li and MeOCOCl afforded the acetylenic ester **(19) (78%).** The requisite methyl group was stereospecifically delivered by cuprate<sup>9</sup> addition to **(19)** leading to the desired  $E \alpha$ ,  $\beta$ -unsaturated ester **(20)** (75%) which upon exposure to **Bun4NF** underwent desilylation and concomitant cyclization to give the lactone **(21)** (80% yield).

<sup>\*\* &</sup>lt;sup>1</sup>H N.m.r. (250 MHz, CDCl<sub>3</sub>, brevetoxin B numbering for ring skeleton). **(17)** : **6** 6.39 (d, *J* 8.39 Hz, lH, CH= CBr,), 5.93 (dd, J 10.34 and 2.09 Hz, 1H, c-ring-CH=), 5.82 (m, 1H, CH<sub>2</sub>CH=CH<sub>2</sub>), 5.55 (dd, *J* 10.21 and 2.09 Hz, c-ring -CH=), 5.10 (m, 2H, C=CH<sub>2</sub>), 4.25 (m, lH, H-ll), 4.14 (dd, *J* 9.31 and 8.50 Hz, lH, H-4), 3.58 (m, lH, H-5) 3.46 (dd, *J* 12.56 and 3.74 Hz, H-7), 2.51-2.11 (m, 1H, CH<sub>2</sub>CH=), 2.18 (m, lH, H-6), 1.85 (d, J4.93 Hz, lH, OH), 1.70 (ddd, *J* 11.45, **11.44,and11.45Hz,lH,H-6),and1.30(s,3H,Me).** (24):65.96(dd, *J* 10.35 and 1.96 **Hz,** lH, c-ring-CH=), 5.54 (dd, *J* 10.25 and 2.04 Hz, lH, c-ring -CH=), 5.33 (br. **s,** lH, A-ring -CH=), 4.81 (br. **s,** lH, >CHOMe), 4.67 (dd, *J* 10.30 and 10.30 Hz, lH, H-11), 3.95 (br. d, *J*  12.01 Hz, lH, H-4), 3.68 **(s,** 3H, C02Me), 3.67-3.51 **(mi,** lH, H-5), 3.42 (dd, *J* 13.21 and 3.84 Hz, lH, H-7), 3.36 **(s,** 3H, OMe), 2.53 (m, 2H, CH2C02Me), 2.12 (m, lH, H-6), 1.70 (m, lH, H-6), 1.69 **(s,** 3H, Me-3), and 1.26 **(s,** 3H, Me-8).



Scheme 2. Synthesis of the ABC ring system of brevetoxin B. *Reagents and conditions:* (a), i, CH<sub>2</sub>=CHCH<sub>2</sub>SiMe<sub>3</sub> (1.5 equiv.), TiCl<sub>4</sub> (1.0 equiv.), CH<sub>2</sub>Cl<sub>2</sub>, -78 °C  $(95\%, \text{ } ca. 10:1$  stereoselectivity), ii, K<sub>2</sub>CO<sub>3</sub> (0.1 equiv.), MeOH, 25 °C, 100%; (b), p-MeC<sub>6</sub>H<sub>4</sub>-S02Cl (1.5 equiv.), pyridine, 0 "C; (c), NaCN (2.0 equiv.), Me2S0, *70* "C, *87%;* (d), Bui2A1H (2.5 equiv.), CH2C12, *-78* "C, **92%;** (e), Ph<sub>3</sub>P=CHCO<sub>2</sub>Me (1.2 equiv.), C<sub>6</sub>H<sub>6</sub>, 25 °C, 86%; (f), (COCl)<sub>2</sub> (1.5 equiv.), Me<sub>2</sub>SO (2.0 equiv.), Et<sub>3</sub>N (5.0 equiv.), CH<sub>2</sub>Cl<sub>2</sub>, -78 to 0 °C; (g), AlMe<sub>3</sub> (4.0 equiv.), CH<sub>2</sub>Cl<sub>2</sub>, -78 overall from (11); (13): (14 imidazole, CH2C12, 0-25"C, 100%; ii, Bui2A1H (2.5 equiv.), CH2C12 -78"C, *87%;* iii, ButOOH **(4.0** equiv.), Ti(PriO), **(3.0** equiv.), (+)-diethyl tartrate (4.0 equiv.),  $CH_2Cl_2$ ,  $-23$  °C,  $72\%$ ; (i), i,  $SO_3$ -pyridine (4.0 equiv.),  $Et_3N$  (5.0 equiv.),  $Me_2SO-CH_2Cl_2$  $(1:1)$ ,  $0^{\circ}C$ ; ii, CBr<sub>4</sub>  $(2.0^{\circ}$  equiv.), PPh<sub>3</sub>  $(4.0^{\circ}$  equiv.), CH<sub>2</sub>Cl<sub>2</sub>,  $-78^{\circ}C$ , 63% overall from  $(15)$ ; iii, Bu<sup>n</sup><sub>4</sub>NF, tetrahydrofuran (THF), **-40** to 0 **"C;** (j) camphorsulphonic acid (CSA) (0.1 equiv.), CH2C12, 25 "C, **93%** overall from **(16);** (k), ButMe2SiC1 (1.1 equiv.), imidazole (2.2 equiv.), dimethylformamide (DMF), 0 °C, 100%; (1), Bu<sup>n</sup>Li (2.2 equiv.), THF,  $-78$  °C, then MeOCOCl (3.0 equiv.), 78%; (m), MeMgCl (6.0 equiv.), CuI **(3.0** equiv.), THF, *-78* "C, *75%;* (n), Bun4NF (1.1 equiv.), THF, 0 "C, *80%;* (o), Bui2AIH (1.2 equiv.), CH2C12, -78 °C, 100%; (p), p-MeC<sub>6</sub>H<sub>4</sub>SO<sub>3</sub>H (0.1 equiv.), CH<sub>2</sub>Cl<sub>2</sub>, 0–25 °C, 91%; (q) KMnO<sub>4</sub> (0.1 equiv.), NaIO<sub>4</sub> (4.0 equiv.), K<sub>2</sub>CO<sub>3</sub> (4.0 equiv.), K<sub>2</sub>CO<sub>3</sub> (4.0 equiv.), C<sub>6</sub>H<sub>6</sub>, (4.0 equiv.), C<sub>6</sub>H<sub>6</sub>, (4.0 equiv.) 25 "C, **9070, (24): (25),** *ca.* 1 *:5;* (s), LiCH,P(O)(OMe),, THF, **-20** "C, *65%;* (t), Bui2A1H (2.2 equiv.), CH2C12, *-78* to 25 "C, 95%; (u), p-ClC<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>Cl (1.2 equiv.), pyridine, 0-25 °C, 90%.

Reduction (Bui2A1H) of **(21)** followed by methoxy acetal formation (MeOH, p-MeC6H4S03H) led to **(23)** (exclusively P-methoxy epimer, 91% overall) *via* the lactol **(22).** Chemoselective oxidative cleavage of the terminal alkene<sup>10</sup> followed by methylation of the resulting carboxylic acid led to the methyl ester **(24)\*\*** (84% overall). As expected, the appendage on ring *c* was found to be easily epimerizable<sup>11</sup> to its thermodynamically more stable  $\alpha$ -isomer under basic conditions, thus serving as a precursor to **(25)** [KOBut, **(24)** : **(25)** *ca.* **<sup>1</sup>**: 5, **94%** yield] and thence to derivatives  $(26)$ — $(28)$ . A preliminary X-ray crystal structure determination of the **p-chlorobenzenesulphonate (28)** (Scheme 2) supported the stereochemical assignments for these potential key intermediates of a projected brevetoxin B **(1)** synthesis.

Extension of this strategy to lower and higher ring homologues and the total synthesis of brevetoxin B **(1)** are continuing.

K. C. N. is a recipient of a Camille and Henry Dreyfus Teacher-Scholar Award 1980-85 and J. **S.** Guggenheim Fellow 1984-85. This work was financially supported by the National Institutes of Health and Merck, Sharp & Dohme.

*Received, 5th June 1985; Corn. 776* 

## **References**

1 Y. Y. Lin, M. Risk, M. **S.** Ray, D. Van Engen, J. Clardy, J. Golik, J. C. James, and K. Nakanishi, *J. Am. Chem. Soc.,* **1981, 103, 6773.** 

- **2 A** number of related epoxide openings can be found in Kishi's elegant synthesis of monensin: **G.** Schmid, T. Fukuyama, K. Akasaka, and **Y.** Kishi, *J. Am. Chem.* **SOC., 1979, 101, 259;** T. Fukuyama, C.-L. J. Wang, and **Y.** Kishi, *ibid.,* **1979, 101, 260.**  See also **A. S.** Rao, **S.** K. K. Paknikar, and J. G. Kirtane, *Tetrahedron,* **1983, 39,2323** and references cited therein.
- **3** For a set of rules for ring closure see: J. E. Baldwin,J. *Chem. Soc., Chem. Commun.,* **1976, 734.**
- **4 S.** Danishefsky and **J. F.** Kerwin, Jr., *J. Org. Chem.,* **1982, 47, 3803.**
- *5* **S. L.** Huang, **A. J.** Mancuso, and D. Swern, J. *Org. Chem.,* **1978, 63, 2480.**
- **6** E. C. Ashby and J. T. Laemimle, *Chem. Rev.,* **1975, 75, 521.**
- **7** T. Katsuki and K. B. Sharpless, *J. Am. Chem. SOC.,* **1980, 102, 5976.**
- **8** E. **J.** Corey and **P.** L. Fuchs, *Tetrahedron Lett.,* **1972, 3769.**
- 9 E. J. Corey and J. **A.** Katzenellenbogen,J. *Am. Chem.* Soc., **1969, 91, 1851.**
- 10 C. **W.** J. Chang, K. N. Iyer, and **S.** W. Pelletier, *J. Org. Chem.,*  **1970,35,3535.**
- **11** R. D. Dawe and **B.** Frazer-Reid, *J. Chem. SOC., Chem. Commun.,*  **1981, 1180.**